XERS logo

Xeris Biopharma Holdings Inc. (XERS)

$16.80

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on XERS

Market cap

$3.07B

EPS

-0.04

P/E ratio

--

Price to sales

5.7

Dividend yield

--

Beta

0.822819

Price on XERS

Previous close

$16.70

Today's open

$16.83

Day's range

$16.39 - $16.94

52 week range

$5.25 - $16.98

Profile about XERS

CEO

John Shannon

Employees

435

Headquarters

Chicago, IL

Exchange

Nasdaq Global Select

Shares outstanding

182700038

Issue type

Common Stock

XERS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on XERS

Top 3 Health Care Stocks That May Collapse This Month

As of Nov. 16, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

news source

Benzinga • Nov 16, 2026

news preview

Xeris Biopharma: Time For A Pause

Xeris Biopharma Holdings has more than doubled since my March buy rating, driven by strong Q3 results and raised guidance. XERS posted a surprise GAAP profit of $0.06 per share, $11.3M net income, and 44% revenue growth to $107.2M, exceeding expectations. Gross margins improved to 88%, and Xeris eliminated $34M of convertible notes, reducing annual interest by $3M and strengthening its balance sheet.

news source

Seeking Alpha • Nov 12, 2026

news preview

Xeris Biopharma Q3 Earnings Call Highlights

Xeris Biopharma NASDAQ: XERS raised its 2026 revenue guidance and its 2030 outlook after third-quarter sales increased 44% year over year, driven by rapid growth in its Cushing syndrome treatment Recorlev.

news source

MarketBeat • Nov 6, 2026

news preview

Xeris Biopharma Holdings, Inc. (XERS) Q3 2026 Earnings Call Transcript

Xeris Biopharma Holdings, Inc. ( XERS ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Cristi Barnett - Vice President of Investor Relations John Shannon - Chairman & CEO Steven Pieper - Chief Financial Officer Conference Call Participants Roanna Clarissa Ruiz - Leerink Partners LLC, Research Division David Amsellem - Piper Sandler & Co., Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Presentation Operator Hello, everyone.

news source

Seeking Alpha • Nov 6, 2026

news preview

Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced its financial results and business highlights for the third quarter ended September 30, 2026. “As a biopharmaceutical leader in endocrine and rare diseases, our strong third quarter performance puts us on a new growth curve tha.

news source

Business Wire • Nov 5, 2026

news preview

Xeris Biopharma (XERS) Surpasses Q3 Earnings and Revenue Estimates

Xeris Biopharma (XERS) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to break-even earnings per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Xeris Biopharma (XERS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Xeris Biopharma (XERS) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Xeris Biopharma Welcomes Menassie M. Taddese to Board of Directors

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced the appointment of Menassie M. Taddese to its Board of Directors, effective today. Taddese will also serve on the Board's Audit Committee. “We are delighted to welcome Menassie to the Xeris Board,” said John Shannon, Chairman a.

news source

Business Wire • Nov 2, 2026

news preview

Xeris Biopharma to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a leading, endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines, today announced it will release its financial results and business highlights for the third quarter ended September 30, 2026, before the open of the U.S. financial markets on Thursday, November 5, 2026. Management will host a conference call.

news source

Business Wire • Oct 22, 2026

news preview

Xeris Biopharma Reinforces Leadership in Endocrinology With Data Disclosures Spanning Commercial Portfolio and Pipeline at Multiple Scientific Meetings

CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REINFORCES LEADERSHIP IN ENDOCRINOLOGY WITH DATA DISCLOSURES SPANNING COMMERCIAL PORTFOLIO & PIPELINE AT MULTIPLE SCIENTIFIC MEETINGS.

news source

Business Wire • Oct 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Xeris Biopharma Holdings Inc.

Open an M1 investment account to buy and sell Xeris Biopharma Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in XERS on M1